



Standard BioTools Expands SomaScan Offering with Advanced Antibody Profiling

November 21, 2024

The KREX™ offering provides additional high plex proteomic solutions for biopharma and translational research end markets

SOUTH SAN FRANCISCO, Calif. November 21, 2024 -- Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools" or the "Company") today announced the addition of KREX™ precision antibody profiling services and kits to its SomaScan™ suite of solutions. The expanded offering enables the detection of autoantibody biomarkers and protein interactions for basic, translational and clinical research.

This expanded offering strengthens Standard BioTools' proteomics portfolio, particularly in biopharma and translational research, by combining the proprietary immunoproteomic technology with its market leading SomaScan platform. Available as an end-to-end lab service or kit, the KREX™ technology empowers pharmaceutical companies and leading research institutions to enhance disease understanding and accelerate biomarker discovery.

"Our enhanced SomaScan platform, powered in part by the complementary KREX™ technology, represents another step forward in our ability to address the needs of biopharma and translational research," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Fitting squarely within our 'omics as a service offering, we're excited to offer customers expanded SomaScan functionality, enabling deeper insights and more impactful discoveries."

Standard BioTools developed this service offering through its acquisition of Sengenics, an innovative functional proteomics company. The terms of the transaction were not disclosed.

About Standard BioTools Inc.

Standard BioTools, the parent company of SomaLogic, Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the Company's expectations with respect to future performance and development of its technologies, the use of the Company's technologies to expand life sciences markets and research, and market and growth opportunity and potential. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of the merger and the integration of SomaLogic, Inc., including the potential for it to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from the merger with SomaLogic, Inc., including the anticipated decrease in operational expenses, at the levels it expects; possible integration, restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company's development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company's plans, or both; risks that the Company's expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company's business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company's products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company's research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding

other related risks, see the "Risk Factors" section of the Company's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on March 1, 2024, and in the Company's other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

Investor Contact

David Holmes
Gilmartin Group LLC
ir@standardbio.com

Media Contact

Dan Moore / Tali Epstein
Collected Strategies
LAB-CS@collectedstrategies.com